Association of clinical and epidemiological characteristics with COVID-19 BNT162b2 mRNA vaccine short-term adverse reactions in healthcare workers

Figures & data

Table 1. Distribution of the demographic characteristics of 502 healthcare workers participating in the study

Variable	Frequency n (%)
Gender
Female	393 (78.3)
Male	109 (21.7)
Age group (years)
<30	47 (9.4)
30–39	91 (18.1)
40–49	117 (23.3)
50–59	158 (31.5)
≥60	89 (17.7)
BMI (kg/m^2)
<25	272 (54.2)
25–29.9	163 (32.5)
≥30	67 (13.3)
Smoking
No	363 (72.3)
Yes	139 (27.7)
Underlying diseases
No	262 (52.2)
Yes	240 (47.8)
Blood type
O	167 (33.3)
A	148 (29.5)
B	43 (8.6)
AB	17 (3.4)
NA	127 (25.2)

Abbreviations: BMI: body mass index; NA: not available.

Table 2. Logistic derived odds ratio (OR) together with 95% confidence interval (95% CI) for local adverse reactions (LARs) following the first and second dose of the BNT162b2 vaccine by the study variables. Cumulative score includes local injection site pain and edema

Variable	Vaccine dose	Local injection pain	Local injection edema	Cumulative score of LARs
Gender (female vs male)	1st	1.53	1.02	1.32
		0.91–2.56	0.53–1.94	0.84–2.09
	2nd	1.56	1.07	1.39
		0.98–2.48	0.59–1.95	0.91–2.13
Age group (10 years more)	1st	0.73	0.97	0.82
		0.60–0.89	0,77–1.22	0.69–0.96
	2nd	0.92	0.9	0.91
		0.78–1.09	0.73–1.11	0.78–1.05
BMI (1 category more)	1st	0.68	1.15	0.82
		0.50–0.93	0.79–1.68	0.62–1.07
	2nd	0.98	1.23	1.08
		0.74–1.31	0.87–1.74	0.84–1.39
Underlying disease (Yes vs No)	1st	1.05	0.81	0.95
		0.66–1.67	0.47–1.41	0.64–1.40
	2nd	1.23	0.82	1.06
		0.82–1.84	0.5–1.37	0.74–1.53
Smoking (Yes vs No)	1st	0.88	1.57	1.15
		0.54–1.44	0.9–2.74	0.76–1.75
	2nd	0.57	1.22	0.72
		0.37–0.87	0.72–2.08	0.49–1.07

Abbreviations: BMI: body mass index;

Statistically significant (p-value < 0.05) results are marked in bold.

Table 3. Logistic derived odds ratio (OR) together with 95% confidence interval (95% CI) for systemic adverse reactions (SARs) following the first and second dose of the BNT162b2 vaccine by the study variables. Cumulative score includes fatigue, headache, myalgias-arthralgias, fever, gastrointestinal symptoms, lymphadenopathy and chills

Variable	Vaccine dose	Fatigue	Headache	Myalgias-Arthralgias	Fever	GI symptoms	LA	Chills	Cumulative score of SARs
Gender (female vs male)	1st	2.61	2.57	2.37	0.72	0.75	0.83	-	2.57
		1.14–5.95	1.13–5.86	0.90–6.25	0.05–9.69	0.07–7.83	0.06–12.15	-	1.39–4.73
	2nd	2.06	2.73	3.08	1.78	1.87	1.87	3.59	2.71
		1.26–3.35	1.53–4.86	1.73–5.49	0.83–3.84	0.51–6.90	0.51–6.90	1.06–12.24	1.76–4.19
Age group (10 years more)	1st	0.90	0.87	0.89	0.47	0.81	0.31	-	0.85
		0.72–1.12	0.69–1.09	0.68–1.16	0.15–1.48	0.35–1.87	0.08–1.25	-	0.71–1.01
	2nd	0.74	0.78	0.70	0.65	0.62	0.58	0.57	0.66
		0.63–0.87	0.66–0.93	0.59–0.83	0.51–0.82	0.38–1.00	0.38–0.89	0.42–0.76	0.57–0.76
BMI (1 category more)	1st	0.83	0.89	1.06	0.80	0.45	0.92	-	0.95
		0.55–1.24	0.61–1.31	0.68–1.66	0.09–6.80	0.06–3.56	0.11–7.96	-	0.70–1.29
	2nd	0.84	1.05	0.97	0.69	0.74	1.42	0.90	0.97
		0.64–1.11	0.78–1.41	0.73–1.30	0.44–1.07	0.29–1.88	0.71–2.85	0.53–1.52	0.76–1.23
Underlying disease (Yes vs No)	1st	0.92	1.55	1.05	-	0.48	-	-	1.08
		0.54–1.58	0.91–2.67	0.56–2.00	-	0.05–4.90	-	-	0.70–1.65
	2nd	0.97	0.88	1.09	1.41	1.81	0.83	2.13	1.05
		0.66–1.43	0.58–1.34	0.72–1.64	0.81–2.48	0.57–5.75	0.30–2.31	1.04–4.37	0.75–1.48
Smoking (Yes vs No)	1st	0.87	1.01	1.49	1.81	0.96	2.06	-	1.12
		0.48–1.57	0.56–1.79	0.78–2.85	0.15–21.29	0.10–9.47	0.17–25.22	-	0.71–1.77
	2nd	0.72	0.83	1.14	1.03	0.87	0.57	1.37	0.81
		0.47–1.09	0.53–1.32	0.74–1.77	0.56–1.90	0.23–3.25	0.16–2.04	0.65–2.89	0.56–1.17

Abbreviations: BMI: body mass index; GI: gastrointestinal; LA: lymphadenopathy

Statistically significant (p-value < 0.05) results are marked in bold.